What is the appropriate treatment for heavy menstrual bleeding in a 48-year-old woman with a history of breast cancer who is not taking any medications?

Treatment Recommendation for Heavy Menstrual Bleeding in a 48-Year-Old Woman with History of Breast Cancer

For this patient with a history of breast cancer, the levonorgestrel-releasing intrauterine system (LNG-IUS) is the most appropriate first-line treatment for heavy menstrual bleeding, as it provides highly effective local hormonal therapy with minimal systemic absorption, avoiding the contraindicated estrogen-containing options.

Rationale and Treatment Algorithm

Contraindicated Treatments

The history of breast cancer fundamentally changes the treatment landscape. Estrogen-containing therapies (combined oral contraceptives) and systemic hormone therapy are contraindicated in women with a history of breast cancer due to increased risk of recurrence 1. This eliminates several standard first-line options used in women without this history.

First-Line Treatment: LNG-IUS

The LNG-IUS should be your primary recommendation because:

• Highly effective: Comparable efficacy to endometrial ablation or hysterectomy for reducing menstrual blood loss 2
• Local action: Minimal systemic hormonal absorption, making it safer in breast cancer survivors compared to systemic hormonal treatments
• Long-term success: 43% of women continue using LNG-IUS at 10 years, with only 29% requiring surgical intervention over a decade 3, 4
• Quality of life improvement: Sustained improvements in quality of life measures over 10 years 3

Second-Line Non-Hormonal Options

If the patient declines LNG-IUS or it's not tolerated, use these non-hormonal alternatives:

Tranexamic acid (antifibrinolytic):

• Reduces menstrual blood loss by 40-60% 5
• More effective than NSAIDs for heavy menstrual bleeding 6, 7
• No increased thrombotic risk demonstrated in long-term Swedish studies despite historical concerns 6
• Typical dosing: 5-7 days during menstruation

NSAIDs (mefenamic acid or naproxen):

• Reduce menstrual blood loss by 20-60% 5
• Less effective than tranexamic acid but still superior to placebo 7, 8
• Additional benefit of treating dysmenorrhea
• Typical dosing: 5-7 days during menstruation

Treatment Sequence

1. Offer LNG-IUS first - highest efficacy with acceptable safety profile in breast cancer survivors
2. If declined or contraindicated: Tranexamic acid (most effective non-hormonal option)
3. If tranexamic acid fails or not tolerated: NSAIDs (mefenamic acid or naproxen)
4. Combination therapy: NSAIDs can be added to tranexamic acid for additional benefit 2

Critical Pitfalls to Avoid

• Do not prescribe combined oral contraceptives - these contain estrogen and are contraindicated 1
• Avoid systemic estrogen therapy - increases breast cancer recurrence risk 1
• Do not use oral luteal-phase progestogens - ineffective for reducing menstrual bleeding in ovulating women 5
• Screen for anemia - up to one-third of women with HMB develop iron deficiency anemia; check hemoglobin and consider iron studies 9

Special Considerations at Age 48

At 48 years old, this patient is perimenopausal. Consider:

• Natural resolution: HMB may resolve with menopause within a few years
• Symptom severity: Balance treatment intensity against proximity to menopause
• Surgical options: Reserve hysterectomy or endometrial ablation for medical treatment failures, given her age and potential for natural resolution

When to Escalate

Refer for surgical evaluation if:

• Medical treatments fail after adequate trials (typically 3-6 months each)
• Severe anemia develops despite treatment
• Structural abnormalities identified on imaging (fibroids, polyps)
• Patient preference for definitive management

The evidence strongly supports starting with LNG-IUS in this population, with tranexamic acid as the preferred non-hormonal alternative, both offering substantial improvements in quality of life with low surgical intervention rates over 10 years 3, 4.